Pragmatic Use of Next-generation Sequencing for Management of Drug-resistant Tuberculosis
Recruiting
N/A
Interventional Study
Drug-resistant Tuberculosis
HIV Coinfection
Cost-Benefit Analysis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Sex
- Any
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 2,500 (estimated)
- Sponsor
- University of California, San Francisco · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
TS ELiOT is a stepped-wedge, cluster randomized trial assessing the effect of a next-generation sequencing-based strategy on rifampin-resistant tuberculosis management and patient outcomes.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Active RR-TB diagnosed at a study facility during the study period
2. Positive Mtb culture, smear, or specimen derivative (e.g., GenoLyse remnant, Xpert cartridge extract)
Exclusion Criteria:
1. Patient expects to relocate/move residence outside of the study region
2. Patie…
Contacts
Rob Warren, PhD
CONTACT